AU2022419971A1 - Use of interferon as an adjuvant in vaccines - Google Patents

Use of interferon as an adjuvant in vaccines Download PDF

Info

Publication number
AU2022419971A1
AU2022419971A1 AU2022419971A AU2022419971A AU2022419971A1 AU 2022419971 A1 AU2022419971 A1 AU 2022419971A1 AU 2022419971 A AU2022419971 A AU 2022419971A AU 2022419971 A AU2022419971 A AU 2022419971A AU 2022419971 A1 AU2022419971 A1 AU 2022419971A1
Authority
AU
Australia
Prior art keywords
seq
antigen
acid sequence
nucleic acid
expression cassette
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022419971A
Other languages
English (en)
Inventor
Linda Helena HAUGE
Oyvind Haugland
Marius Andre de Feijter KARLSEN
Marit Rode
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Publication of AU2022419971A1 publication Critical patent/AU2022419971A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/38011—Tombusviridae
    • C12N2770/38022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022419971A 2021-12-20 2022-12-19 Use of interferon as an adjuvant in vaccines Pending AU2022419971A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163291585P 2021-12-20 2021-12-20
US63/291,585 2021-12-20
PCT/US2022/081916 WO2023122526A1 (en) 2021-12-20 2022-12-19 Use of interferon as an adjuvant in vaccines

Publications (1)

Publication Number Publication Date
AU2022419971A1 true AU2022419971A1 (en) 2024-07-04

Family

ID=85221940

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022419971A Pending AU2022419971A1 (en) 2021-12-20 2022-12-19 Use of interferon as an adjuvant in vaccines

Country Status (12)

Country Link
US (1) US20250057946A1 (https=)
EP (1) EP4452313A1 (https=)
JP (1) JP2025501740A (https=)
CN (1) CN118434443A (https=)
AU (1) AU2022419971A1 (https=)
CA (1) CA3243028A1 (https=)
CL (1) CL2024001831A1 (https=)
CO (1) CO2024007500A2 (https=)
CR (1) CR20240245A (https=)
DK (1) DK202470173A1 (https=)
MX (1) MX2024007696A (https=)
WO (1) WO2023122526A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations
DK202370610A1 (en) * 2022-12-13 2024-07-12 Zoetis Services Llc Methods of vaccine administration to salmonids
CN118956807B (zh) * 2024-10-17 2025-01-24 天津赛萌生物技术有限公司 一种组蛋白乙酰基转移酶突变体及其在生物大分子制备中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
CA2650730A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
WO2014118385A1 (en) * 2013-02-04 2014-08-07 University of Tromsø The use of dna sequences encoding an interferon as vaccine adjuvants
GB201415789D0 (en) 2014-09-05 2014-10-22 Touchlight Genetics Ltd Synthesis of DNA
US10456459B2 (en) 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
CN109844134B (zh) 2016-08-16 2023-05-05 塔驰莱特Ip有限公司 闭合线性dna的生产
GB201805683D0 (en) 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
GB202002068D0 (en) 2020-02-14 2020-04-01 Touchlight Ip Ltd DNA synthesis yield improvements

Also Published As

Publication number Publication date
JP2025501740A (ja) 2025-01-23
DK202470173A1 (en) 2024-07-12
EP4452313A1 (en) 2024-10-30
CN118434443A (zh) 2024-08-02
MX2024007696A (es) 2024-07-01
CR20240245A (es) 2024-09-13
CA3243028A1 (en) 2025-04-07
CL2024001831A1 (es) 2024-10-18
US20250057946A1 (en) 2025-02-20
CO2024007500A2 (es) 2024-07-29
WO2023122526A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
Bosch-Camós et al. African swine fever vaccines: a promising work still in progress
US20250057946A1 (en) Use of interferon as an adjuvant in vaccines
US20250127873A1 (en) Compositions and methods for prevention of piscine myocarditis
RU2519210C2 (ru) Вакцины, содержащие генетические варианты парвовируса собак
KR20210092762A (ko) 아프리카 돼지 열병 바이러스에 대한 면역원성 조성물
US11744888B2 (en) Method of treating or preventing clinical signs caused by infectious bronchitis virus with 4/91 IBV vaccine having heterologous spike protein
JP2018535251A (ja) ブタサーコウイルス３型免疫原性組成物、その製造方法、およびその使用方法
CN113666990A (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
US11696947B2 (en) H52 IBV vaccine with heterologous spike protein
US20250057937A1 (en) Compositions and methods for expressing antigens on cell membrane
WO2025027551A2 (en) Ibv vaccine with heterologous dmv/1639 spike protein
RU2854997C2 (ru) Использование интерферона в качестве адьюванта в вакцинах
RU2842174C2 (ru) Композиции и способы профилактики миокардита рыб
US20100247624A1 (en) Vaccine compositions and methods containing an immunogen derived from equine arteritis virus
Maity MASTERS OF VETERINARY SCIENCE